The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1050 - 1057 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5407 İndeks Tarihi: 14-12-2022
The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
Öz: Background/aim: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact with programmed cell death protein 1 (PD-1), causing immunosuppression. The aim of our study is to examine the correlation between the serum sPD-1 and sPD-L1 levels and clinicopathological characteristics in patients with nonsmall cell lung cancer. We also compared our results with the healthy population (control group). Materials and methods: Thirthy-seven nonsmall cell lung cancer (NSCLC) patients who were operated in our clinic were included in our study. The control group included fifteen healthy patients. The sPD-1 and sPD-L1 levels were measured in serum samples by using the ELISA method. Results: The preoperative sPD-1 and sPD-L1 levels were significantly higher in the study group compared to the control group (44.12 ± 22.25 pg/mL vs. 18.54 ± 6.56 pg/mL; p = 0.001 and 26.15 ± 18.03 pg/mL vs. 10.29 ± 3.08 pg/mL; p = 0.001, respectively). There was a statistically significant decline in serum sPD-1 and sPD-L1 levels at the preoperative and postoperative 1st, 7th, and 30th days following surgical resection (44.12 ± 22.25 pg/mL, 37.86 ± 18.02 pg/mL, 36.33 ± 18.36 pg/mL, 34.14 ± 13.71 pg/mL; p = 0.007 and 26.15 ± 18.03 pg/mL, 20.60 ± 15.50 pg/mL, 18.31 ± 14.04 pg/mL, 13.64 ± 10.60 pg/mL; p = 0.001, respectively).There was a positive correlation between the preoperative and postoperative 30th day serum sPD-1 levels and the tumor size (p = 0.031, r = 0.352; p = 0.024, r = 0.371; respectively). We also found a positive correlation between the preoperative and postoperative 30th day serum sPD-L1 levels and pleural invasion (p = 0.001, p = 0.001; respectively), and the N category (p = 0.015, p = 0.013; respectively). Conclusion: We think that sPD-1 and sPD-L1 levels may be used as a potential biomarker for lung cancer screening, prediction of the stage, and besides to detect recurrences and/or metastases following resection in NSCLC following validation with multicenter and larger-scale prospective trials.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. The Lancet Oncology 2012; 13(8): 790-801.doi: 10.1016/S1470-2045(12)70211-5
- 2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 2012; 12(4): 252-264. doi: 10.1038/nrc3239
- 3. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation 2015; 125(9): 3384-3391.doi: 10.1172/JCI80011
- 4. Jia L, Zhang Q, Zhang R. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biology & Medicine 2018; 15(2): 116-123. doi: 10.20892/j.issn.2095-3941.2017.0086
- 5. He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non- small cell lung cancer. Scientific Reports 2015; 5(1): 1-9. doi: 10.1038/srep13110
- 6. Ji M, Liu Y, Li Q, Li XD, Zhao WQ et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine 2015; 13(1): 1-6. doi: 10.1186/s12967-014-0373-0
- 7. Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology & Oncology 2018; 11(1): 1-26.doi: 10.1186/ s13045-018-0578-4
- 8. Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers 2020; 12(2): 473. doi: 10.3390/cancers12020473
- 9. Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 2017; 8(57): 97671-97682. doi: 10.18632/oncotarget.18311
- 10. Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y et al. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer 2017; 104: 1-6.doi: 10.1016/j.lungcan.2016.11.023
- 11. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018; 68(6): 394- 424.doi: 10.3322/caac.21492
- 12. Li Y, Cui X, Yang YJ, Chen QQ, Zhong Let al. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients. Clinical Breast Cancer 2019; 19(5): 326-332. doi: 10.1016/j.clbc.2019.03.008
- 13. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Translational Lung Cancer Research 2014; 3(4): 242- 249.doi: 10.3978/j.issn.2218-6751.2013.12.05
- 14. Li N, Zhou Z, Li F, Sang J, Han Q et al. Circulating soluble programmed death-1 levels may differentiate immune- tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 2017; 8(28): 46020-46033.doi: 10.18632/ oncotarget.17546
- 15. He J, Pan Y, Guo Y, Li B, Tang Y. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients. Journal of Immunotherapy 2020; 43(5): 156- 164.doi: 10.1097/CJI.0000000000000315
- 16. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clinical Cancer Research 2011; 17(7): 1915-1923.doi: 10.1158/1078-0432.CCR-10-0250
- 17. Chen Y, Wang Q, Shi B, Xu P, Hu Z et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD- L1+ cell lines. Cytokine 2011; 56(2): 231-238.doi: 10.1016/j. cyto.2011.06.004
- 18. Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y et al. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer. Clinical Lung Cancer 2018; 19(5): 410-417. doi: 10.1016/j. cllc.2018.04.014
- 19. Cheng S, Zheng J, Zhu J, Xie C, Zhang X et al. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer. The International Journal of Biological Markers 2015;30(4):364- 368. doi: 10.5301/jbm.5000170
- 20. Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post- cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PloS one 2011; 6(9): e23621.doi: 10.1371/journal.pone.0023621
- 21. Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PloS one 2019; 14(2): e0212978.doi: 10.1371/journal.pone.0212978
- 22. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98(2):413-423.doi: 10.1002/cncr.11464
- 23. Zheng Z, Bu Z, Liu X, Zhang L, Li Z et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chinese Journal of Cancer Research 2014;26(1):104-111.doi: 10.3978/j.issn.1000-9604.2014.02.08
| APA | ANCIN B, Ozercan M, Yilmaz Y, UYSAL S, Kumbasar U, SARIBAS Z, Dikmen E, Doğan R, Demircin M (2022). The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. , 1050 - 1057. 10.55730/1300-0144.5407 |
| Chicago | ANCIN BURCU,Ozercan Mesut Melih,Yilmaz Yigit,UYSAL SERKAN,Kumbasar Ulaş,SARIBAS Zeynep,Dikmen Erkan,Doğan Rıza,Demircin Metin The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. (2022): 1050 - 1057. 10.55730/1300-0144.5407 |
| MLA | ANCIN BURCU,Ozercan Mesut Melih,Yilmaz Yigit,UYSAL SERKAN,Kumbasar Ulaş,SARIBAS Zeynep,Dikmen Erkan,Doğan Rıza,Demircin Metin The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. , 2022, ss.1050 - 1057. 10.55730/1300-0144.5407 |
| AMA | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. . 2022; 1050 - 1057. 10.55730/1300-0144.5407 |
| Vancouver | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. . 2022; 1050 - 1057. 10.55730/1300-0144.5407 |
| IEEE | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M "The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients." , ss.1050 - 1057, 2022. 10.55730/1300-0144.5407 |
| ISNAD | ANCIN, BURCU vd. "The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients". (2022), 1050-1057. https://doi.org/10.55730/1300-0144.5407 |
| APA | ANCIN B, Ozercan M, Yilmaz Y, UYSAL S, Kumbasar U, SARIBAS Z, Dikmen E, Doğan R, Demircin M (2022). The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Turkish Journal of Medical Sciences, 52(4), 1050 - 1057. 10.55730/1300-0144.5407 |
| Chicago | ANCIN BURCU,Ozercan Mesut Melih,Yilmaz Yigit,UYSAL SERKAN,Kumbasar Ulaş,SARIBAS Zeynep,Dikmen Erkan,Doğan Rıza,Demircin Metin The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Turkish Journal of Medical Sciences 52, no.4 (2022): 1050 - 1057. 10.55730/1300-0144.5407 |
| MLA | ANCIN BURCU,Ozercan Mesut Melih,Yilmaz Yigit,UYSAL SERKAN,Kumbasar Ulaş,SARIBAS Zeynep,Dikmen Erkan,Doğan Rıza,Demircin Metin The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1050 - 1057. 10.55730/1300-0144.5407 |
| AMA | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Turkish Journal of Medical Sciences. 2022; 52(4): 1050 - 1057. 10.55730/1300-0144.5407 |
| Vancouver | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients. Turkish Journal of Medical Sciences. 2022; 52(4): 1050 - 1057. 10.55730/1300-0144.5407 |
| IEEE | ANCIN B,Ozercan M,Yilmaz Y,UYSAL S,Kumbasar U,SARIBAS Z,Dikmen E,Doğan R,Demircin M "The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients." Turkish Journal of Medical Sciences, 52, ss.1050 - 1057, 2022. 10.55730/1300-0144.5407 |
| ISNAD | ANCIN, BURCU vd. "The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients". Turkish Journal of Medical Sciences 52/4 (2022), 1050-1057. https://doi.org/10.55730/1300-0144.5407 |
